Rubicon Research Reports Q2 Results: Standalone Net Profit Reaches 824.49 Million, Group Income Stands at ₹800.49 Million

Rubicon Research Reports Q2 Results: Standalone Net Profit Reaches 824.49 Million, Group Income Stands at ₹800.49 Million​

Rubicon Research Limited today released its unaudited financial results for the quarter ended June 30, 2026, detailing strong performance in both standalone and consolidated operations. The company reported a Net Profit after tax of 824.49 million in its standalone segment, while the Group recorded a Total Comprehensive Income of 800.49 million.

The standalone financial results for Rubicon Research Limited showed total income reaching 4,301.41 million, derived from 4,277.30 million in revenue from operations and 24.11 million in other income. The company recorded total expenses of 3,194.84 million, leading to a Profit before tax of 1,106.57 million. After a net tax expense of 282.08 million, the Net Profit after tax for the period was 824.49 million, with basic earnings per share standing at 4.99 in ₹.

Key operational data points from the quarter included an expenditure incurred on research and development revenue amounting to 596.76 million.

The unaudited consolidated financial results for the Group reflected a scale increase, reporting total income of 5,400.21 million. The Group’s revenue from operations was recorded at 5,343.38 million, with other income totaling 56.83 million. After accounting for total expenses of 4,296.49 million, the Group registered a Profit before tax of 1,103.72 million. Following the net tax expense of 255.91 million, the Net Profit after tax was 847.81 million.

Quarterly Financial Performance Overview (₹ in millions)​

The financial performance metrics for Rubicon Research Limited and its subsidiaries across multiple periods are summarized below:

Consolidated Group Performance and Strategic Developments​

The consolidated results for the quarter ended June 30, 2026, showed significant activity from the parent company and its subsidiaries. The Group recorded total income of 5,400.21 million. Expenses amounted to 4,296.49 million, and the resultant Net Profit after tax was 847.81 million.

Two major strategic movements were noted in the quarterly results:

• Acquisition: The company entered into a definitive agreement to acquire an 85% stake in Arinna Lifesciences Limited for a total consideration of ₹1,759.17 million. This transaction was completed on April 30, 2026.
• Amalgamation: The Board approved the Scheme of Amalgamation of Kia Health Tech Private Limited with Rubicon Research Limited. Although filed with the Registrar of Companies on August 3, 2026, no accounting effect of this proposed amalgamation has been given in these financial results as the scheme has not yet become effective.

IPO Proceeds and Capital Structure Details​

The utilization of net proceeds received from a fresh issue of equity shares during the previous year ended March 31, 2026, was reported across both standalone and consolidated results (totaling 4,712.74 million before estimated IPO expense). The funds utilized up to June 30, 2026, stood at 3,907.05 million, leaving an unutilised amount of 805.69 million.

The utilization breakdown for the initial proceeds was as follows:


The timeline for the utilization of the unutilised IPO proceeds has been extended up to March 31, 2027.

RUBICON Stock Price Movement​

Shares of Rubicon Research Limited today slipped by 0.24% to close at ₹1619.1, reflecting a slight downturn in its stock performance. The equity saw robust trading activity, with a total volume of 257,007 shares recorded during the day.